Paper Details

  1. Home
  2. Paper Details

A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.

Author: CousinsMichael, IrvingGordon, KleoudisChristi S, MortensenEric R, PierceAmy, PénzesJanos, RamjattanBrian, RauckRichard, SnidowJerry W, SpieringsEgilius L H, WurzelmannJohn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alvimopan, a peripherally acting mu-opioid receptor antagonist, was studied for its effectiveness in treating opioid-induced constipation (OIC) in a 12-week, double-blind, placebo-controlled trial in patients receiving opioids for non-cancer pain. Alvimopan showed numerical superiority over placebo in improving OIC symptoms and reducing the need for rescue laxatives. The treatment was well tolerated and did not antagonize opioid analgesia.
Paper Details　
Original Abstract of the Article :
The balance between the pain relief provided by opioid analgesics and the side effects caused by such agents is of particular significance to patients who take opioids for the long-term relief of non-cancer pain. The spectrum of signs and symptoms affecting the gastrointestinal (GI) tract associated...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jpain.2010.06.013

データ提供：米国国立医学図書館（NLM）

Alvimopan: A New Hope for Opioid-Induced Bowel Dysfunction

Opioid analgesics play a crucial role in pain management, but their use can often lead to unpleasant side effects, particularly opioid-induced bowel dysfunction (OIBD). This research focuses on the potential of alvimopan, a peripherally acting mu-opioid receptor antagonist, as a treatment option for long-term OIBD in patients with non-cancer pain. The study, published in 2010, conducted a double-blind, placebo-controlled trial to assess the effectiveness of alvimopan in alleviating OIBD symptoms.

Alvimopan's Promise: A Potential Solution to OIBD

The results of this research show promise for alvimopan as a potential treatment option for OIBD. [The study] indicated that alvimopan was numerically superior to placebo in improving opioid-induced bowel dysfunction symptoms. The study found that alvimopan was well tolerated and did not antagonize opioid analgesia. These findings suggest that alvimopan could offer a valuable treatment option for patients experiencing OIBD, allowing them to manage their pain without experiencing the debilitating gastrointestinal side effects often associated with opioid use.

Living with Opioid-Induced Bowel Dysfunction: A New Perspective

This research offers a glimmer of hope for patients who struggle with OIBD, a common problem often associated with long-term opioid use. The study's findings suggest that alvimopan could potentially alleviate the debilitating gastrointestinal symptoms associated with OIBD, improving quality of life for those relying on opioids for pain management.

Dr.Camel's Conclusion

Like a camel finding a wellspring of water in a desolate desert, this research offers a potential solution to the challenges of opioid-induced bowel dysfunction. The findings suggest that alvimopan could be a valuable tool in managing OIBD, paving the way for better pain management and improved quality of life for patients.

Date :
  1. Date Completed 2012-01-09
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

21292168

DOI: Digital Object Identifier

10.1016/j.jpain.2010.06.013

Related Literature

Article Analysis
・Side Effects of alvimopan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.